British AstraZeneca corona vaccine, limited effect on South African mutants | Reuters

[Reuters]–AstraZeneca, a major British pharmaceutical company, announced on the 6th that the new coronavirus vaccine jointly developed with Oxford University in the UK had limited effect on mildly ill patients infected with the South African mutant strain as a result of initial clinical trials. did.

The Financial Times (FT) reported on the 6th that the vaccine was extremely ineffective against South African mutants, according to a study conducted by the University of the Witwatersland and Oxford University in South Africa.

A AstraZeneca spokeswoman told the newspaper that “small Phase 1 and 2 clinical trials had limited effect on mildly ill patients.” However, “Since the clinical trial was conducted mainly for healthy young people, the effect on critically ill patients and inpatients has not been confirmed accurately,” he said.

According to the FT newspaper, none of the 2026 clinical trial investigators were hospitalized and there were no deaths.

According to a spokeswoman, the development of a vaccine for the South African mutant has already begun, and the corresponding vaccine is expected to be shipped in the fall.